The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205
A molecular marker of artemisinin-resistant Plasmodium falciparum malaria
Ariey, F., Witkowski, B., Amaratunga, C., Beghain, J., Langlois, A.-C., Khim, N., Kim, S., Duru, V., Bouchier, C., Ma, L., et al. (2014) · Nature · doi:10.1038/nature12876 · Cited by 2,090
Chemistry: Chemical con artists foil drug discovery
Baell, J., & Walters, M. A. (2014) · Nature · doi:10.1038/513481a · Cited by 1,043
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Thousands of chemical starting points for antimalarial lead identification
Gamo, F.-J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.-L., Vanderwall, D. E., Green, D. V. S., Kumar, V., Hasan, S., et al. (2010) · Nature · doi:10.1038/nature09107 · Cited by 996
Franzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M. T., Cook, M. B., Quenzer, V. K., Ferguson, R. M., et al. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.2.362-366.1998 · Cited by 964
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 875
Foamy macrophages and the progression of the human tuberculosis granuloma
Russell, D. G., Cardona, P.-J., Kim, M.-J., Allain, S., & Altare, F. (2009) · Nature Immunology · doi:10.1038/ni.1781 · Cited by 827
Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease
Molina, I., Gómez i Prat, J., Salvador, F., Treviño, B., Sulleiro, E., Serre, N., Pou, D., Roure, S., Cabezos, J., Valerio, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313122 · Cited by 604
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3262 · Cited by 603
A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria
Mbengue, A., Bhattacharjee, S., Pandharkar, T., Liu, H., Estiu, G., Stahelin, R. V., Rizk, S. S., Njimoh, D. L., Ryan, Y., Chotivanich, K., et al. (2015) · Nature · doi:10.1038/nature14412 · Cited by 597
Chemical genetics of Plasmodium falciparum
Guiguemde, W. A., Shelat, A. A., Bouck, D., Duffy, S., Crowther, G. J., Davis, P. H., Smithson, D. C., Connelly, M., Clark, J., Zhu, F., et al. (2010) · Nature · doi:10.1038/nature09099 · Cited by 566
A historical perspective on the discovery of statins
ENDO, A. (2010) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.86.484 · Cited by 548
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
Braselmann, S., Taylor, V., Zhao, H., Wang, S., Sylvain, C., Baluom, M., Qu, K., Herlaar, E., Lau, A., Young, C., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.109058 · Cited by 508
Drug discovery in pharmaceutical industry: productivity challenges and trends
Khanna, I. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.007 · Cited by 479
Riss, T., Moravec, R. A., Niles, A. L., Duellman, S. J., Benink, H. A., Worzella, T. J., & Minor, L. K. (2016) · Europe PMC (PubMed Central) · Cited by 469
Plouffe, D., Brinker, A., McNamara, C., Henson, K., Kato, N., Kuhen, K., Nagle, A., Adrián, F., Matzen, J. T., Anderson, P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802982105 · Cited by 449
Malaria medicines: a glass half full?
Wells, T. N. C., van Huijsduijnen, R. H., & Van Voorhis, W. C. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4573 · Cited by 430
Self-citationTun, K. M., Imwong, M., Lwin, K. M., Win, A. A., Hlaing, T. M., Hlaing, T., Lin, K., Kyaw, M. P., Plewes, K., Faiz, M. A., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70032-0 · Cited by 414
Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines
Swinney, D. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.236 · Cited by 413
Targeting mammalian target of rapamycin (mTOR) for health and diseases
Tsang, C. K., Qi, H., Liu, L. F., & Zheng, X. F. S. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.008 · Cited by 406
Ivermectin, 'Wonder drug' from Japan: the human use perspective
CRUMP, A., & OMURA, S. (2011) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.87.13 · Cited by 368
Camptothecin and Taxol: Historic Achievements in Natural Products Research
Oberlies, N. H., & Kroll, D. J. (2004) · Journal of Natural Products · doi:10.1021/np030498t · Cited by 353
Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery
Meister, S., Plouffe, D. M., Kuhen, K. L., Bonamy, G. M. C., Wu, T., Barnes, S. W., Bopp, S. E., Borboa, R., Bright, A. T., Che, J., et al. (2011) · Science · doi:10.1126/science.1211936 · Cited by 338
Microbial phenotypic heterogeneity and antibiotic tolerance
Dhar, N., & McKinney, J. D. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.12.007 · Cited by 333
An update on pharmacotherapy for leishmaniasis
Sundar, S., & Chakravarty, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.973850 · Cited by 320
Chagas Disease Drug Discovery: Toward a New Era
Chatelain, E. (2015) · SLAS Discovery · doi:10.1177/1087057114550585 · Cited by 312
Cho, S. H., Warit, S., Wan, B., Hwang, C. H., Pauli, G. F., & Franzblau, S. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00055-06 · Cited by 292
Quinolone-3-Diarylethers: A New Class of Antimalarial Drug
Nilsen, A., LaCrue, A. N., White, K. L., Forquer, I. P., Cross, R. M., Marfurt, J., Mather, M. W., Delves, M. J., Shackleford, D. M., Saenz, F. E., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005029 · Cited by 292
Self-citationDesigning the next generation of medicines for malaria control and eradication
Burrows, J. N., Hooft van Huijsduijnen, R., Möhrle, J. J., Oeuvray, C., & Wells, T. N. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-187 · Cited by 282
Self-citationThe life and times of ivermectin — a success story
Õmura, S., & Crump, A. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1048 · Cited by 273
Peña, I., Pilar Manzano, M., Cantizani, J., Kessler, A., Alonso-Padilla, J., Bardera, A. I., Alvarez, E., Colmenarejo, G., Cotillo, I., Roquero, I., et al. (2015) · Scientific Reports · doi:10.1038/srep08771 · Cited by 260
Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions
Harper, J., Skerry, C., Davis, S. L., Tasneen, R., Weir, M., Kramnik, I., Bishai, W. R., Pomper, M. G., Nuermberger, E. L., & Jain, S. K. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir786 · Cited by 256
Treatment of visceral leishmaniasis
Lockwood, D., & Moore, E. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62883 · Cited by 242
Franzblau, S. G., DeGroote, M. A., Cho, S. H., Andries, K., Nuermberger, E., Orme, I. M., Mdluli, K., Angulo-Barturen, I., Dick, T., Dartois, V., et al. (2012) · Tuberculosis · doi:10.1016/j.tube.2012.07.003 · Cited by 217
Datta, M., Via, L. E., Kamoun, W. S., Liu, C., Chen, W., Seano, G., Weiner, D. M., Schimel, D., England, K., Martin, J. D., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424563112 · Cited by 207
Advancing Drug Innovation for Neglected Diseases—Criteria for Lead Progression
Nwaka, S., Ramirez, B., Brun, R., Maes, L., Douglas, F., & Ridley, R. (2009) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000440 · Cited by 198
Strader, C. R., Pearce, C. J., & Oberlies, N. H. (2011) · Journal of Natural Products · doi:10.1021/np2000528 · Cited by 196
Gilbert, I. H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400362b · Cited by 190
DON, R., & IOSET, J.-R. (2014) · Parasitology · doi:10.1017/s003118201300142x · Cited by 180
Bosman, A., & Mendis, K. N. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.193 · Cited by 180
Angulo-Barturen, I., Jiménez-Díaz, M. B., Mulet, T., Rullas, J., Herreros, E., Ferrer, S., Jiménez, E., Mendoza, A., Regadera, J., Rosenthal, P. J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002252 · Cited by 163
Rycker, M. D., Hallyburton, I., Thomas, J. C., Campbell, L. A., Wyllie, S., Joshi, D., Cameron, S., Gilbert, I. H., Wyatt, P. G., Frearson, J. A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02398-12 · Cited by 160
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits
Wunberg, T., Hendrix, M., Hillisch, A., Lobell, M., Meier, H., Schmeck, C., Wild, H., & Hinzen, B. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03700-1 · Cited by 152
Role of hERG potassium channel assays in drug development
Priest, B. T., Bell, I. M., & García, M. I. (2008) · Channels · doi:10.4161/chan.2.2.6004 · Cited by 151
Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents
Lakshminarayana, S. B., Huat, T. B., Ho, P. C., Manjunatha, U. H., Dartois, V. A., Dick, T., & Rao, S. P. S. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku457 · Cited by 151
History of the discovery of cyclosporin and of its early pharmacological development.
Borel, J. F. (2002) · PubMed · Cited by 123
Mak, P. A., Rao, S. P. S., Tan, M. P., Lin, X., Chyba, J., Tay, J. A., Ng, S. H., Tan, B. H., Cherian, J., Duraiswamy, J., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb2004884 · Cited by 121
Clark, R. L. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.05.002 · Cited by 118
Deng, X., Kokkonda, S., Mazouni, F. E., White, J. C., Burrows, J. N., Kaminsky, W., Charman, S. A., Matthews, D. J., Rathod, P. K., & Phillips, M. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500481t · Cited by 113
Self-citationMalaria and artemisinin derivatives: an updated review
Ansari, M. T., Saify, Z. S., Sultana, N., Ahmad, I. N., Saeed-ul-Hassan, S., Tariq, I., & Khanum, M. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575113136660097 · Cited by 91
The search for new sterilizing anti-tuberculosis drugs
Denis, A. M. (2004) · Frontiers in bioscience · doi:10.2741/1293 · Cited by 89
Drug resistance genomics of the antimalarial drug artemisinin
Winzeler, E. A., & Manary, M. J. (2014) · Genome biology · doi:10.1186/s13059-014-0544-6 · Cited by 77
Sinden, R. E., Carter, R., DRAKELEY, C. J., & Leroy, D. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-70 · Cited by 72
Novel Mutations in K13 Propeller Gene of Artemisinin-ResistantPlasmodium falciparum
Isozumi, R., Uemura, H., Kimata, I., Ichinose, Y., Logedi, J., Omar, A. H., & Kaneko, A. (2015) · Emerging infectious diseases · doi:10.3201/eid2103.140898 · Cited by 72
High-Throughput Screening: The Hits and Leads of Drug Discovery- An Overview
Martis, E. A. F., & Radhakrishnan (2011) · Cited by 70
In Vitro Model of Hypoxically Induced Nonreplicating Persistence of Mycobacterium tuberculosis
Wayne, L. G. (2003) · Humana Press eBooks · doi:10.1385/1-59259-147-7:247 · Cited by 69
Hawn, T. R., Shah, J. A., & Kalman, D. (2015) · Immunological Reviews · doi:10.1111/imr.12255 · Cited by 66
Advances in drug discovery and biochemical studies
Kita, K., Shiomi, K., & Ōmura, S. (2007) · Trends in Parasitology · doi:10.1016/j.pt.2007.03.005 · Cited by 54
Self-citation[Treatment of visceral leishmaniasis].
CARMONA, M. D. (1954) · PubMed · Cited by 47
Apoptosis stalks Plasmodium falciparum maintained in continuous culture condition
Mutai, B. K., & Waitumbi, J. N. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-s3-s6 · Cited by 45
Silva‐Miranda, M., Ekaza, E., Breiman, A., Asehnoune, K., Barros-Aguirre, D., Pethe, K., Ewann, F., Brodin, P. M., Ballell, L., & Altare, F. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03705-14 · Cited by 44
New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
Leibert, E. M., Rom, W. N., & DANCKERS, M. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s37743 · Cited by 37
Malaria runs rings round artemisinin
Burrows, J. N. (2015) · Nature · doi:10.1038/nature14387 · Cited by 13
Self-citationElliott, R. (2011) · Topics in medicinal chemistry · doi:10.1007/978-3-642-23487-3 · Cited by 3
Cited by
New developments in anti-malarial target candidate and product profiles
Burrows, J. N., Duparc, S., Gutteridge, W. E., Hooft van Huijsduijnen, R., Kaszubska, W., Macintyre, F., Mazzuri, S., Möhrle, J. J., & Wells, T. N. C. (2017) · Malaria Journal · doi:10.1186/s12936-016-1675-x · Cited by 520
Self-citationVan Voorhis, W. C., Adams, J. H., Adelfio, R., Ahyong, V., Akabas, M. H., Alano, P., Alday, A., Alemán Resto, Y., Alsibaee, A., Alzualde, A., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005763 · Cited by 435
Self-citationCarroll, A. R., Copp, B. R., Davis, R. A., Keyzers, R. A., & Prinsep, M. R. (2021) · Natural Product Reports · doi:10.1039/d0np00089b · Cited by 347
Natural Products as a Source for Novel Antibiotics
Moloney, M. G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.001 · Cited by 308
Carroll, A. R., Copp, B. R., Davis, R. A., Keyzers, R. A., & Prinsep, M. R. (2022) · Natural Product Reports · doi:10.1039/d1np00076d · Cited by 269
Metadata
- Authors
- Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-10-05
- Volume
- 14
- Issue
- 11
- Pages
- 751-758
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2198907191
- Cited by
- 607
- References
- 70
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.